Health Canada changes filing requirements for product monographs: Notice

March 10, 2023
Our file number: 23-101262-834

Health Canada is currently making changes to the second language product monograph submission requirements for human drugs.

The second language product monograph is no longer required at the time of submission or during review if the document is available in both official languages ​​in the following portals:

This amendment applies to the following product monographs:

  • Biological drugs (Appendix D)
  • Radiopharmaceuticals (Annex C)
  • Pharmaceutical drugs (prescription and non-prescription)

Product labels and package inserts are not affected by this change.

The final second language product monograph must be submitted after the issuance of the Notice of Compliance (NOC), Drug Identification Number (DIN) or Letter of No Objection (LNO).

The second language product monograph is still required as outlined in the plain language labeling guide for prescription and non-prescription drugs if:

  • It is available in one language only on the BDPP and PMPS or
  • The product of the monograph in question has not yet been authorized
Product Monograph (PM) available on the DPD online Deposit During the exam Post-authorization
None Preferably available in both official languages
The PM must be provided at least in the first language
PM in second language (if not already provided) Final PM in second language
One official language Document preferably available in both official languages
The PM must be provided at least in the first language
PM in second language (if not already provided) Final PM in second language
Both official languages First language only S.O. Final PM in second language

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.